Opposing roles of ZEB1 in the cytoplasm and nucleus control cytoskeletal assembly and YAP1 activity

dc.contributor.authorGuo, Yan
dc.contributor.authorLu, Xiaoqin
dc.contributor.authorChen, Yao
dc.contributor.authorClark, Geoff
dc.contributor.authorTrent, John
dc.contributor.authorCuatrecasas Freixas, Miriam
dc.contributor.authorEmery, Douglas
dc.contributor.authorSong, Zhao-Hui
dc.contributor.authorChariker, Julia
dc.contributor.authorRouchka, Eric
dc.contributor.authorPostigo, Antonio
dc.contributor.authorLiu, Yongqing
dc.contributor.authorDean, Douglas C.
dc.date.accessioned2023-08-30T09:36:39Z
dc.date.available2023-08-30T09:36:39Z
dc.date.issued2022-10-04
dc.date.updated2023-08-30T09:36:39Z
dc.description.abstractEpithelial-mesenchymal transition (EMT) facilitates cancer invasion and is initiated by mesenchyme-driving transcription factors and actin cytoskeletal assembly. We show a cytoplasmic-to-nuclear transport gradient of the EMT transcription factor Zeb1 toward sites of invasion in lung adenocarcinoma (LUAD), driven by the EMT inducer Tgfb, which is expressed in M2 polarized macrophages. We show that Zeb1 binds free actin monomers and RhoA in the cytoplasm to inhibit actin polymerization, blocking cell migration and Yap1 nuclear transport. Tgfb causes turnover of the scaffold protein Rassf1a, which targets RhoA. Release of this RhoA inhibition in response to Tgfb overcomes Zeb1's block of cytoskeleton assembly and frees it for nuclear transport. A ZEB1 nuclear transport signature highlights EMT progression, identifies dedifferentiated invasive/metastatic human LUADs, and predicts survival. Blocking Zeb1 nuclear transport with a small molecule identified in this study inhibits cytoskeleton assembly, cell migration, Yap1 nuclear transport, EMT, and precancerous-to-malignant transition.
dc.format.extent19 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec729720
dc.identifier.idimarina9330989
dc.identifier.issn2211-1247
dc.identifier.pmid36198275
dc.identifier.urihttps://hdl.handle.net/2445/201624
dc.language.isoeng
dc.publisherElsevier
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.celrep.2022.111452
dc.relation.ispartofCell Reports, 2022, vol. 41, num. 1, p. 111452
dc.relation.urihttps://doi.org/10.1016/j.celrep.2022.111452
dc.rightscc-by-nc-nd (c) Guo, Yan et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0*
dc.sourceArticles publicats en revistes (Fonaments Clínics)
dc.subject.classificationCàncer
dc.subject.classificationCàncer de pulmó
dc.subject.classificationCèl·lules canceroses
dc.subject.classificationFactors de transcripció
dc.subject.classificationProteïnes
dc.subject.classificationCitosquelet
dc.subject.otherCancer
dc.subject.otherLung cancer
dc.subject.otherCancer cells
dc.subject.otherTranscription factors
dc.subject.otherProteins
dc.subject.otherCytoskeleton
dc.titleOpposing roles of ZEB1 in the cytoplasm and nucleus control cytoskeletal assembly and YAP1 activity
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
729720.pdf
Mida:
6.43 MB
Format:
Adobe Portable Document Format